COMBATTING CHALLENGING ASPECTS OF CANCER WITH THIOSEMICARBAZONES
Keywords:
Thiosemicarbazones, Anti-tumour activity, Cell lines, In vitro and in vivo studiesAbstract
Cancer claims the second largest number of deaths across the globe every year. With the new addition and discoveries in the therapeutic area, there are also some serious challenges which come into play. These include the emergence of resistance, malignancy, relapses and some life-threatening adverse effects. These challenges further intensify the need to discover better alternatives. Thiosemicarbazones have been explored extensively against many resistant and non-resistant forms of cancer in vitro as well as in vivo. Chelation of iron and copper has been attributed to their activity as anticancer agents, but recent studies have revealed few more complex mechanisms of their action. With different approaches to target different aspects of cancers, they have gained ample attention. Structural variations of these compounds were found to be highly selective in their action.
Downloads
References
Qu JQ, Sun GC, Wang LF, Qu L. Synthesis, characterization, and biological activities of some transition metal(II) complexes with the thiosemicarbazone derived from 4-[1-(4methylphenylsulfonyl)-1-indol-3-yl]but-3-en-2-one. Chem Pap 2006;60:214–9.
Brockman RW, Thomson JR, Bell MJ, Skipper HE. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res 1956;16:167.
Sartorelli AC, Booth BA. Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal Bis-(thiosemicarbazone). Cancer Res 1967;27:1614–9.
Yogeeswari P, Sriram D, Saraswat V, Ragavendran JV, Kumar MM, Murugesan S, et al. Synthesis and anticonvulsant and neurotoxicity evaluation of N4-phthalimido phenyl (thio) semicarbazides. Eur J Pharm Sci 2003;20:341.
Ramachandran R, Rani M, Kabilan S. Design, synthesis and biological evaluation of novel 2-[(2,4-diaryl-3-azabicyclo[3.3.1]nonan-9-ylidene)hydrazono]-1,3-thiazolidin-4-ones as a new class of antimicrobial agents. Bioorg Med Chem Lett 2009;19:2819-23.
Yogeeswari P, Banerjee D, Bhat P, Thomas A, Srividya M, Shriram D. Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection. Eur J Med Chem 2011;46:106-21.
Britta EA, Scariot DB, Falzirolli H, Nakamura TU, Silva CC, Nakamura CV, et al. Cell death and ultrastructural alterations in Leishmania amazonensis caused by new compound 4-nitrobenzaldehyde thiosemicarbazone derived from S-limonene. BMC Microbiol 2014;14:236.
Klayman DL, Bartosevich JF, Griffin TS, Mason CJ, Scovill JP. 2-Acetylpyridine thiosemicarbazones: A new class of potential antimalarial agents. J Med Chem 1979;22:855-62.
Lukevlcs E, Demlcheva L, Erchak N, Germane S. Synthesis and anticancer activity of furfural thiosemicarbazones. Appl Organomet Chem 1993;7:543-51.
Du X, Guo C, Hansell E, Doyle PS, Caffrey CR, Holler TP, et al. Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem 2002;45:2695–707.
Domagk G, Behnisch R, Mietzsch F, Schimidt H. On a new class of compounds effective in vitro against Tubercle bacilli. Naturwissenchaften 1946;33:315.
Kune GA. To-day’s drugs: methisazone. Br Med J 1964;2:621.
Beraldo H. Vanadium complexes with 2-pyridineformamide thiosemicarbazones: in vitro studies of insulin like activity. Inorg Chim Acta 2009;362:414-20.
Soares AA. Isatin-3-N4-benzilthiosemicarbazone: a non-toxic thiosemicarbazone derivative, protects and reactivates rat and human cholinesterases inhibited by methamidophos in vitro and in silico. Toxicol In Vitro 2012;26:1030-9.
Blower PJ, Dilworth JR, Maurer RI, Mullen GD, Reynolds CA, Zheng Y. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J Inorg Biochem 2001;85:15.
Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321.
Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000;14:323.
Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171.
Shipman C, Smith SH, Drach JC, Klayman DL. Thiosemicarbazones of 2-acetylpyridine, 2-acetylquinoline, 1-acetylisoquinoline, and related compounds as inhibitors of herpes simplex virus in vitro and in a cutaneous herpes guinea pig model. Antiviral Res 1986;6:197.
Cancer Fact Sheet N 297. World Health Organisation; 2014.
Defining Cancer. National Cancer Institute; 2013.
Kalinowski DS, Quach P, Richardson DR. Thiosemicarbazones: the new wave in cancer treatment. Future Med Chem 2009;1:1143–51.
Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica 2014;99:672–8.
Jansson PJ, Kalinowski DS, Lane JR, Kovacevic Z, Seebacher NA, Fouani L. et al. The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the Triad of Death†in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacol Res 2015;100:255–60.
Chen J, Huang YW, Liu G, AfrT asiabi Z, Sinn E, Padhye S. The cytotoxicity and mechanisms of 1,2-naphthoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol Appl Pharmacol 2004;197:40–8.
Zheng LM, Li J, King I, Doyle TW, Chen SH. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr Med Chem 2001;2:121-3.
Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007;446:749–57.
Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411–24.
Jansson PJ, Yamagishi T, Arvind A, Seebacher N, Gutierrez E, Stacy A, et al. Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J Biol Chem 2015;290:9588–603.
Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. P-Glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 2013;288:31761–71.
Maruyama Y, Ono M, Kawahara A, Yokoyam T, Basaki Y, Kage M, et al. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res 2006;66:6233–42.
Fang BA, Kovacevic Z, Park KC, Kalinowski DS, Jansson PJ, Lane DJ, et al. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim Biophys Acta 2014;1845:1–19.
Sun J, Zhang D, Bae DH, Sahni S, Jansson P, Zheng Y, et al. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis 2013;34:1943–54.
Maruyama Y, Ono M, Kawahara A, Yokoyama T, Basaki Y, Kage M, et al. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res 2006;66:6233–42.
Bae DH, Jansson PJ, Huang ML, Kovacevic Z, Kalinowski D, Lee CS, et al. The role of NDRG1 in the pathology and potential treatment of human cancers. J Clin Pathol 2013;66:911–7.
Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, et al. The NDRG-1 gene suppresses tumor metastasis in prostate cancer, Cancer Res 2003;63:1731–6.
Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004;104:2967–75.
Altintop MD, Atlii O, Iigin S, Demirel R, Ozdemir A, Kaplancikli ZA. Synthesis and biological evaluation of new naphthalene substituted thiosemicarbazone derivatives as potential antifungal and anticancer agents. Eur J Med Chem 2016;108:406-14.
Vikneswaran R, Eltayeb NE, Ramesh S, Yahya R. New alicyclic thiosemicarbazone chelated zinc(II) antitumor complexes: Interactions with DNA/protein, nuclease activity and inhibition of topoisomerase-I. Polyhedron 2016;105:89–95.
Hussein MA, Iqbal MA, Umar MI, Haque RA, Teoh SG. Synthesis, structural elucidation and cytotoxicity of new thiosemicarbazone derivatives. Arabian J Chem 2015. Doi:10.1016/J.Arabjc.2015.08.013. [Article in Press]
De Oliveira JF, da Silva AL, Vendramini-Costa DB, da Cruz Amorim CA, Campos JF, Rebeiro AG, et al. Synthesis of thiophene thiosemicarbazone derivatives and evaluation of their in vitro and in vivo antitumor activities. Eur J Med Chem 2015;104:148-56.
Ali AQ, Teoh SG, Salhin A, Eltayeb NE, Khadder Ahamed MB, Abdul Majid AM. Synthesis of isatin thiosemicarbazones derivatives: in vitro anti-cancer, DNA binding and cleavage activities. Spectrochim Acta Part A 2014;125:440–8.
Shahriar SMS, Ali SMM, Jesmin M, Islam MK, Mondal S. In vivo anticancer activity of vanillin, benzophenone and acetone thiosemicarbazones on Swiss albino mice. J Coastal Life Med 2014;2:811-6.
Xie W, Xie S, Zhou Y, Tnag S, Liu J, Yang W, et al. Design and synthesis of novel 5,6-disubstituted pyridine-2,3-dione-3-thiosemicarbazones derivatives as potential anticancer agents. Eur J Med Chem 2014;81:22-7.
Ali MM, Jesmin M, Islam MK, Khatun F, Azad AK. Antineoplastic activities of acetone thiosemicarbazone against ehrlich ascites carcinoma cells bearing mice. Med J Islamic World Academy Sci 2013;21:97-104
Su W, Qian Q, Li P, Lei X, Xiao Q, Huang S, et al. Synthesis, characterization, and anticancer activity of a series of ketone‑N4‑substituted thiosemicarbazones and their ruthenium(II) arene complexes. Inorg Chem 2013;52:12440−9.
Sampath K, Sathiyaraj S, Jayabalakrishnan C. Evaluation of DNA-binding, DNA cleavage, antioxidant and cytotoxic activity of mononuclear ruthenium(II) carbonyl complexes of benzaldehyde 4-phenyl-3-thiosemicarbazones. Spectrochim Acta Part A 2013;115:287–96.
Halder S, Paul P, Peng SM, Lee GH, Mukherjee A, Dutta S, et al. benzaldehyde thiosemicarbazone complexes of platinum. Syntheses, structures and cytotoxic properties. Polyhedron 2012;45:177–84.
Leovac VM, Bogdanović GA, Jovanović LS, Joksović L, Marković V, Joksović MD, et al. Synthesis, characterization and antitumor activity of polymeric copper(II) complexes with thiosemicarbazones of 3-methyl-5-oxo-1-phenyl-3-pyrazolin-4-carboxaldehyde and 5-oxo-3-phenyl-3-pyrazolin-4-carboxaldehyde. J Inorg Biochem 2011;105:1413–21.
Pingaew R, Prachayasittikul S, Ruchirawat S. Synthesis, cytotoxic and antimalarial activities of benzoyl thiosemicarbazone analogs of isoquinoline and related compounds. Molecules 2010;15:988-96.
Lessa JA, Mendes IC, da Silva PRO, Soares MA, dos Santos RG, Speziali NL, et al. 2-acetylpyridine thiosemicarbazones: cytotoxic activity in nanomolar doses against malignant gliomas. Eur J Med Chem 2010;45:5671-7.
Da Silva AP, Martini MV, CecÃlia MA, Cunha S, João E, Ruiz Ana LTG, et al. Antitumor activity of (+)-a-bisabolol-based thiosemicarbazones against human tumor cell lines. Eur J Med Chem 2010;45:2987-93.
Ferraz KSO, Ferandes L, Carrilho D, Pinto MCX, Leite MF, Fagundes EMS. 2-benzoylpyridine-N-tolyl thiosemicarbazones and their palladium (II) complexes: Cytotoxicity against leukemia cells. Bioorg Med Chem 2009;17:7138–44.
Zheng LP, Chena CL, Zhoua J, Lia MX, Wu YJ. Synthesis, crystal structure and antitumor study of an Iron(III) Complex of 2-acetylpyrazine N-methylthiosemicarbazone. Z Naturforsch 2008;63:1257–61.
Graminha AE, Vilhena FS, Batista AA, Louro SR, Ziolli RL, Teixeira LR, et al. 2-pyridinoformamide-derived thiosemicarbazones and their iron(III) complexes: Potential antineoplastic activity. Polyhedron 2008;27:547–51.
Hernandez W, Paz J, Vaisberg A, Spodine E, Richter R, Beyer L. Synthesis, characterization, and in vitro cytotoxic activities of benzaldehyde thiosemicarbazone derivatives and their palladium(II) and platinum(II) complexes against various human tumor cell lines. Hindawi Publishing Corporation. Bioinorg Chem Appl 2008. Doi.org/10.1155/2008/690952. [Article in Press]
Ferrari MB, Bisceglie F, Pelosi G, Pinelli S, Tarasconi P. Synthesis, characterization, crystal structure and antiproliferative in vitro activity of long-chain aliphatic thiosemicarbazones and their Ni(II) complexes. Polyhedron 2007;26:5150-61.
Hu W, Zhou W, Xia CN, Wen X. Synthesis and anticancer activity of thiosemicarbazones. Bioorg Med Chem Lett 2006;16:2213–8.